Non-Surgical Options May Maintain Relapse-Free Survival in Rectal Cancer Subset
Distance relapse-free survival was maintained in patients with pMMR locally advanced rectal cancer through non-operative management of the disease.
Read More
Perioperative Opdivo Extends Event-Free Survival in Lung Cancer
Receiving perioperative Opdivo for non-small cell lung cancer showed event-free survival benefits compared with placebo.
Herceptin, Perjeta Regimen May Be Effective Without Chemo in Breast Cancer
Among patients with HR+/HER2+ breast cancer, Herceptin and Perjeta plus endocrine therapy proved to be beneficial without chemotherapy.
Long-Term Study Data Support Keytruda as Standard of Care for Advanced Melanoma
Keytruda continued to improve survival versus Yervoy in unresectable stage 3 or 4 melanoma in long-term follow-up data.
Anti-PD-L1 Antibody Drug Combo May Improve Outcomes in Advanced Kidney Cancer
Benmelstobart plus anlotinib significantly improved survival versus Sutent in the first-line treatment of advanced renal cell carcinoma.
Lower Keytruda Doses May Be as Effective as Standard Doses for Stage 4 NSCLC
Patients with stage 4 non-small cell lung cancer may derive an equal benefit with a lower dose of Keytruda versus the standard dose.
Side Effects, Quality of Life Important to Consider in Breast Cancer Subset
Patients with HER2-positive metastatic breast cancer may consider related side effects and quality of life outcomes when choosing treatments.
Cediranib Added to Lynparza Didn’t Improve Progression, Survival in Ovarian Cancer
A Lynparza/cediranib combo had similar results versus standalone Lynparza among patients with relapsed platinum-sensitive ovarian cancer.
Kidney Cancer Questions Answered, From Protein Intake to Clinical Trials
An expert provides answers to readers’ questions regarding different aspects of the kidney cancer experience, such as protein intake and clinical trials.
Imjudo Plus Imfinzi Improve Survival Versus Nexavar in Liver Cancer
In patients with unresectable liver cancer, treatment with Imjudo plus Imfinzi showed better survival outcomes compared with Nexavar.
10 Commonly Asked Lung Cancer Questions With Dr. Jyoti Malhotra
Following a CURE® Educated Patient® Lung Cancer Summit, the City of Hope expert answered 10 commonly asked questions from patients with lung cancer.
Survival Benefit Continues at 10 Years From Opdivo Either Alone or With Yervoy in Advanced Melanoma
Findings from the CheckMate 067 of patients with advanced melanoma include the longest follow-up of a checkpoint inhibitor in any tumor type.
Krazati Associated With Superior Outcomes Than Docetaxel in KRAS G12C+ NSCLC
Krazati’s benefits were seen regardless of baseline brain metastases, researchers have reported in findings from the KRYSTAL-12 trial.
Kidney Cancer FAQs Answered on Treatments, Care Teams and More
An expert provides answers to pressing questions regarding different aspects of a kidney cancer journey, including stage, grade and treatment options.
Imfinzi Improves Survival Outcomes in Subgroups of Patients with LS-SCLC
Among patients with limited-stage small cell lung cancer, the benefits of consolidation Imfinzi were seen across a number of subgroups.
Enhertu Maintains QOL, Slows Pain in HR+/HER2 Metastatic Breast Cancer
Enhertu improved the time it took for patients with a breast cancer subset to experience worsening pain and other symptoms, without affecting overall quality of life.
Patients with Extensive-Stage SCLC May Benefit From Higher I-DXd Dose
A recent study compared two dosages of ifinatamab deruxtecan among patients with extensive-stage small cell lung cancer.
Challenges to Consider While Receiving Fotivda for Kidney Cancer
At the 2024 ESMO Congress, CURE® spoke with an expert about Fotivda and certain challenges patients may experience, such as side effects.
Watch
Keytruda Improves Disease-Free Survival in Some With Urothelial Carcinoma
Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived without signs of cancer.
Braftovi Regimen Is Promising in Metastatic Colorectal Cancer
In patients with BRAF V600E-mutant metastatic colorectal cancer, a combination of Braftovi, Erbitux and chemotherapy showed promising antitumor activity.
Kisqali Plus Aromatase Inhibitor Shows Benefits in HR+/HER2- Breast Cancer
Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset.
Adaptive NSCLC Study Fails to Produce Improved Results, Clinical Benefits in Some
Imfinzi with monalizumab and ceralasertib showed promising long-term benefits in advanced NSCLC, but no other combinations significantly improved results.
Presurgical Cetrelimab With TAR-200 Shows Responses in Muscle-Invasive Bladder Cancer
Patients with muscle-invasive bladder cancer who were treated with presurgical chemotherapy may have a 55% lower risk of death, research shows.
AI May Predict Cancer Mutations in Lung, Other Cancers
An artificial intelligence model was shown to predict tumor mutation burden in lung cancer and other diseases.
Breastfeeding Is OK in Breast Cancer Subset During Hormone Therapy Break
In patients with HR-positive breast cancer who recently gave birth, breastfeeding is OK during a break from receiving hormone therapy.
Targeted Therapy Outperforms Standard Care in Metastatic Solid Cancers
Patients with metastatic disease whose cancers were tested and treated for specific mutations tended to have better outcomes than those given the standard of care.
Therapies for Some With Prostate Cancer Focuses on Reducing Side Effects
At the 2024 ESMO Congress, an expert explained how Nubeqa may reduce fatigue-related side effects in metastatic hormone-sensitive prostate cancer.
Imfinzi Continuously Demonstrates Survival Benefit in Limited Stage SCLC
Patients with limited-stage small cell lung cancer saw improvements in progression-free survival and overall survival with Imfinzi versus placebo.
Perioperative Imfinzi, Neoadjuvant Chemo Improves Survival in Muscle-Invasive Bladder Cancer
Imfinzi and chemotherapy before surgery, followed by Imfinzi after surgery, generated survival benefits in cisplatin-eligible muscle-invasive bladder cancer.
Enhertu Maintains Quality of Life in Metastatic Breast Cancer Subgroup
Enhertu also improved the time to deterioration for pain and other factors in patients with HR-positive, HER2-low and -ultralow metastatic breast cancer.
